20th October 2021
SNG001 progresses to Phase 3 of ACTIV-2 trial
A summary statement covering the latest drug programme activity by Synairgen
Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.
Coronaviruses cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome (SARS) and COVID-19.
Synairgen has peer-reviewed data from the Company’s SG016 trial published in The Lancet Respiratory Medicine journal on 12 November 2020.
Two Phase II trials (SG005 and INEXAS) in asthma, conducted by Synairgen and AstraZeneca respectively, suggest that SNG001 boosts antiviral responses in the lungs.
Over the years, Synairgen has accumulated an extensive BioBank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts.
Managed Access Program For more information on the Managed Access Program please click here.